What Two Regulators Concluded

Drug regulators are not advocates. They are institutionally cautious, procedurally slow, and structurally disinclined to make claims they cannot defend. When a regulator revises a label to add a warning, it has usually been persuaded by evidence it spent years resisting.

This matters for what follows. The strongest support for the proposition that certain anti-malarial drugs can cause lasting neurological and psychiatric harm does not come from campaigners or litigators. It comes from the United States Food and Drug Administration and the European Medicines Agency, in documents written for clinicians, in language chosen to be conservative.

This article sets out what those two bodies concluded. It is the firmest ground in this series, and everything that follows depends on it.

The boxed warning Established

In July 2013, the FDA required a boxed warning on the label for mefloquine. A boxed warning — often called a black box — is the most serious warning the agency issues. It is reserved for risks that may lead to death or serious injury, and it appears at the top of the prescribing information, enclosed in a border, before anything else a clinician reads.

The warning stated that neuropsychiatric adverse reactions associated with the drug can persist long after mefloquine has been discontinued.

That sentence is doing precise work, and it is worth slowing down to notice what it does and does not say. It does not say the drug causes permanent injury in everyone who takes it, or in most people, or in any predictable subset. It says that the adverse reactions — dizziness, anxiety, depression, confusion, hallucinations, and others documented in the label — are not necessarily confined to the period of use. They can outlast it.

The warning went further on one category of effect. Vestibular symptoms — dizziness, loss of balance, ringing in the ears — could in some cases be permanent.

The FDA also issued a clinical instruction: if psychiatric or neurologic symptoms appear during prophylactic use, the drug should be discontinued and an alternative substituted. This is a meaningful detail. Regulators do not typically direct clinicians to abandon a treatment at the first sign of a symptom unless they believe continuation carries a risk that outweighs the inconvenience of switching.

The European review Established

The following year, the European Medicines Agency conducted its own pharmacovigilance review through its Pharmacovigilance Risk Assessment Committee. Its conclusions were, if anything, more direct.

The EMA found evidence supporting a causal relationship between mefloquine and the occurrence of long-lasting and even persistent neuropsychiatric effects. It noted a strong suspicion that the drug could, in some cases, cause permanent brain damage.

It also found something with practical consequences for anyone who took the drug: no identifiable risk factors. The review could not determine in advance who was susceptible. There was no screening test, no set of characteristics, no prior condition that reliably predicted who would experience serious effects and who would not.

Only the advice — to stop taking mefloquine if neuropsychiatric reactions or changes to their mental state occur — can be given as a precautionary measure.

That conclusion has a quiet implication. A precaution that depends on recognising symptoms and acting on them requires that the person taking the drug is in a position to recognise and act. Where the drug is taken under military discipline, on deployment, at prescribed intervals, that condition may not hold.

What these findings do not establish

Regulatory findings describe population-level risk. They do not establish causation in any individual case.

This distinction is easy to lose and important to keep. When the FDA warns that reactions can persist after discontinuation, it is reporting a pattern in adverse-event data across a population of users. It is not stating that any particular person's symptoms were caused by the drug.

Nor do these findings speak to the mechanism. Neither regulator claimed to explain how the drug produces lasting effects. They concluded that the effects occur and can persist. The question of what is happening in the nervous system to produce them is a separate matter, resting on different and considerably weaker evidence — the subject of the next article in this series.

Nor, finally, do these findings represent unanimity. Two national authorities reviewed the evidence on long-term causation and reached different conclusions, both in 2017: Australia's Repatriation Medical Authority declined to issue Statements of Principles for chemically-acquired brain injury from these drugs, citing insufficient sound medical-scientific evidence; and Health Canada's safety review found no conclusive evidence that mefloquine can cause long-lasting and permanent neurological and psychiatric adverse events, while acknowledging a small number of reported cases of permanent vestibular damage.

Those dissents are real and this series will return to them. But they should be read alongside what they dissent from, not in place of it. The disagreement concerns how far the evidence extends, not whether the drug is capable of causing serious neuropsychiatric harm.

Why this is the starting point

The research foundation underlying this series states the position compactly: the quinoline anti-malarials mefloquine and tafenoquine are established neurotoxicants capable of causing lasting neuropsychiatric injury.

That claim rests on regulatory findings, not on advocacy, and it is the load-bearing element of everything that follows.

What the regulators established is limited but solid: mefloquine can cause serious neuropsychiatric effects; those effects can outlast the period of use; some may be permanent; and no one can predict in advance who is at risk.

Everything this series argues afterward is weaker than that.